< Back to previous page

Patent

Combination immunotherapy of IL-15 and CD40 agonist in cancer treatment

The present invention relates to the field of combination immunotherapy, more in particular to a combination comprising IL-15 and a CD40 agonist for use in the treatment of cancer, such as and not limited to, pancreatic cancer (e.g. pancreatic ductal adenocarcinoma and pancreatic neuro-endocrine tumours).
Patent Publication Number: WO2021110930
Year filing: 2021
Year approval: 2022
Year publication: 2021
Status: Requested
Technology domains: undefined
Validated for IOF-key: Yes
Attributed to: Associatie Universiteit & Hogescholen Antwerpen